Bio-Oil recently debuted a brand-new product — Bio-Oil Body Lotion.
Featuring a high-oil formula that is delivered in a nongreasy and ultralight fluid lotion, the product contains natural plant oils, vitamins and antioxidants, the company said.
Suitable for use on hands, arms and legs, the Bio-Oil Body Lotion is vegan, cruelty-free and comes in recyclable packaging.
Designed to spread easily, the lotion is quickly absorbed into the skin, contains 42% oil and does not leave behind a greasy residue. In addition, it also features a thin fluid-like consistency in which the water and oil are very lightly bound together, the company said.
It currently comes in an 8.5-oz. size that retails for $14.99 on Amazon and a 5.9-oz. size that retails for $11.99 on Amazon and for $15.99 at Ulta Beauty.
Cinnamon Toast Crunch is adding a hint of sweetness and heat to the breakfast aisle with its new CinnaFuego Toast Crunch.
The cereal, which combines sweet cinnamon and fiery spices including spicy pepper, looks the same as the original cereal, the brand said.
“CTC is always looking to give our fans the most absurd and exciting experiences,” said Mindy Murray, General Mills senior marketing communications manager. “So when we were thinking about what to do next, we realized snack time was a moment that could be spiced up. We can’t wait for CTC lovers to try CinnaFuego, and if they dare, eat it with some milk for breakfast.”
Sold in a resealable pouch, CinnaFuego Toast Crunch will be available on August 12 exclusively at Walmart.com for a limited time.
Clarvue releases advanced dark site management tool
Clarvue, a leading custom software solutions company, has launched a new dark site management tool to help retailers manage their closed locations.
The tool allows for asset tracking, risk management and mitigation, compliance, lease management, vendor management, and remote monitoring, as well as reduces the operation and financial burden of dark sites from time of announcement, until they are no longer part of the real estate portfolio.
“This rapidly changing retail environment has created a tremendous need for retailers to effectively and efficiently manage dark sites,” said Mike MacKenzie, president and founder of Clarvue.
“The majority of retail management tools are designed to open and operate new and/or existing sites, with very little attention to effective management of closures. There are substantial cost savings and efficiencies retailers can realize with our dark site management tool, and Clarvue is pleased to assist retailers with this overlooked market need,” he said.
“Our platform serves as a single efficiency tool for associates, multiple departments, merchants and outside facility vendors, delivering tangible ROI and financial and operational results,” said Robin Walker, Clarvue’s chief operating officer.
“We have a passion for executing projects that make mundane operations and processes more effective and efficient for all types of retailers — health care, discount, specialty, casual/fast dining — whether they operate a handful or thousands of locations,” Walker said. “In our history, we have managed thousands of different projects over tens of thousands of separate locations.”
Nestlé Toll House brings back seasonal fall-inspired cookie doughs
Nobelpharma America is introducing Hyftor (sirolimus topical gel) 0.2%, the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis complex for patients 6 years and older.
The company made the introduction at the 2022 World TSC Conference at the Hilton Anatole Hotel in Dallas from July 28-31, 2022.
TSC is a rare genetic disease that affects approximately one in 6,000 live births. Nearly one million people worldwide are estimated to have TSC, with approximately 50,000 in the United States. TSC causes non-cancerous tumors, or hamartomas, to form in vital organs, including the skin.
It may also cause facial angiofibromas, which are pink or red bumps usually located on the cheeks, nose and chin that may cause bleeding, itching, redness and significant disfiguration without treatment. Many individuals with TSC also present with autism, epilepsy and other neuropsychiatric disorders.
"We anticipate that we will be able to have robust discussions with healthcare professionals and individuals with TSC who are interested in learning more about Hyftor," said Yoshiki Kida, president and CEO of Nobelpharma America. "We also will have the opportunity to explain the services Nobelpharma will offer the community through our new patient access program, Nobelpharma Connect."
Nobelpharma Connect is a patient hub where patients may learn about eligibility and enrollment in access programs including assistance program, copay program and other support services.
Nobelpharma will begin providing Hyftor through a network of specialty pharmacies in August.
"Nobelpharma is committed to advancing the scientific understanding of TSC and delivering new options to individuals and families impacted by this disease," Kida said. "As we introduce Hyftor, we look forward to strengthening our relationships within the patient community, maintaining a dialogue and listening to their experiences to help shape the future of research and treatment."